文献速递肿瘤 PET/CT骨显像与常规 SPECT

18F-FDG PET/MRI 在组织细胞增生症中较 PET/CT 的诊断增益:前瞻性对比研究

Diagnostic impact of 18F-FDG PET/MRI over PET/CT in histiocytoses: a prospective comparative study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-07-02

这项前瞻性单中心研究纳入15例系统性组织细胞增生症患者,在一次注射后顺序行全身18F-FDG PET/CT与PET/MRI。PET/MRI在33%患者中检出额外病灶或改善已知病灶表征,尤其在中枢神经系统、淋巴结和骨髓,但PET/CT对肺部病灶评估更优。

要点

  • PET/MRI在33%患者中提供额外病灶检出或改善病灶表征。
  • PET/MRI检出全部37个病灶位点,PET/CT检出34个。
  • PET/CT对肺部病灶评估优于PET/MRI。

核心结论

  • 18F-FDG PET/MRI在系统性组织细胞增生症中较PET/CT提供增量诊断价值,尤其在解剖复杂区域的病灶检出和表征方面。
  • PET/MRI可能特别适用于需要重复影像随访的患者,但PET/CT在肺部评估方面仍具优势。

研究设计与样本

  • 前瞻性单中心研究,纳入15例系统性组织细胞增生症患者,在一次放射性示踪剂注射后顺序行全身18F-FDG PET/CT和PET/MRI。
  • 图像由两名核医学医师和一名放射科医师独立评估,共识评价病灶检出、解剖勾画、代谢摄取和疾病范围。

主要发现

  • PET/CT与PET/MRI在14/15例患者(93%)中结果一致。
  • PET/MRI在5/15例患者(33%)中检出额外病灶或改善已知受累部位的表征,尤其在中枢神经系统、淋巴结和骨髓。
  • 共识别37个组织细胞增生症相关病灶位点,PET/MRI检出全部37个,PET/CT检出34个。
  • PET/MRI在60%病例中提供更高的病灶勾画评分,在33%病例中改善病灶表征。
  • 一例进行性认知功能恶化的患者中,仅PET/MRI检出的脑干病灶促使重新评估治疗方案;PET/CT对肺部病灶评估表现更好。

临床怎么用

  • 对于系统性组织细胞增生症患者,可考虑PET/MRI以改善中枢神经系统、淋巴结和骨髓等复杂区域的病灶检出与表征。
  • 需要重复影像随访的患者可能尤其受益于PET/MRI较低的辐射负担。
  • 肺部病灶评估仍应优先选择PET/CT。

局限性

  • 单中心研究,样本量仅15例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Systemic histiocytoses, including Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease, are rare multisystem disorders requiring accurate whole-body assessment for staging, treatment planning, and follow-up. While 18F-FDG PET/CT is the current reference imaging modality, PET/MRI may improve lesion detection and characterization owing to its superior soft-tissue contrast and lower radiation burden. METHODS: In this prospective single-centre study, 15 patients with systemic histiocytosis underwent sequential whole-body 18F-FDG PET/CT and PET/MRI after a single radiotracer injection. Images were independently assessed by two nuclear medicine physicians and one radiologist, with consensus evaluation of lesion detection, anatomical delineation, metabolic uptake, and disease extent. RESULTS: PET/CT and PET/MRI were concordant in 14/15 patients (93%). PET/MRI detected additional lesions or provided improved characterisation of known involved sites in 5/15 patients (33%), particularly in the central nervous system, lymph nodes, and bone marrow. Overall, 37 histiocytosis-attributed lesion sites were identified; PET/MRI detected all 37, whereas PET/CT detected 34. PET/MRI provided higher lesion delineation scores in 60% of cases and improved lesion characterisation in 33%. A brainstem lesion detected only by PET/MRI, in a patient with progressive cognitive deterioration, prompted re-evaluation of the therapeutic plan. PET/CT showed better performance for pulmonary lesion assessment. CONCLUSION: 18F-FDG PET/MRI provided incremental diagnostic value over PET/CT in systemic histiocytoses, particularly for lesion detection and characterization in anatomically complex regions. PET/MRI may be especially useful in patients requiring repeated imaging follow-up, although PET/CT remains advantageous for lung evaluation.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Pudis M, Rocamora-Blanch G, Solanich X, et al. Diagnostic impact of 18F-FDG PET/MRI over PET/CT in histiocytoses: a prospective comparative study. Eur J Nucl Med Mol Imaging. 2026. PMID: 42390561. doi:10.1007/s00259-026-08034-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。